MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Subthalamic stimulation reshapes the reliable inherent brain state in Parkinson’s disease

    C. Chu, N. He, Z. Zeng, Y. Zhang, X. Wang, Z. Zhang, J. Wang, Y. Wang, Z. Jiang, Y. Lu, B. Sun, F. Yan, D. Li, C. Zhang, C. Liu (Tianjin, China)

    Objective: To elucidate the reliable inherent state of resting-state global brain network and explore the state modulation mechanism of subthalamic stimulation (STN-DBS) on Parkinson’s disease…
  • 2023 International Congress

    Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial

    C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

    Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…
  • 2023 International Congress

    LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing

    J. Meredith Jr, K. Kelly, V. Guss, A. Desantis, L. Kimmel, S. Soletsky, J. Pizzano, G. Cadelina, J. Chavez, S. Sparks, A. Cacace (New Haven, USA)

    Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…
  • 2023 International Congress

    Microbiota and Gastrointestinal Manifestations of Parkinson’s Disease with Arabic Translation of Gastrointestinal Dysfunction Scale

    Y. Salah, N. Dawood, M. Salama, A. Shalash (cairo, Egypt)

    Objective: To investigate the frequency of occurrence of gastrointestinal tract GIT symptoms and their relation to patients’ clinical characteristics in addition the characteristics of gut…
  • 2023 International Congress

    An European-Canadian multinational evaluation of access to care in Parkinson disease: a patient perspective

    M. van Munster, E. Crighton, A. Sánchez-Ferro, J. Ferreira, R. Bouça, E. Ruzicka, D. Pedrosa, D. Grimes, T. Mestre (Marburg, Germany)

    Objective: To provide a multi-national perspective of people with Parkinson disease (PwPD) on access to healthcare and the impact of the COVID-19 pandemic on those…
  • 2023 International Congress

    ParkProReakt Study Protocol – A randomized controlled trial to evaluate a proactive approach to health care in Parkinson’s disease

    M. van Munster, J. Stümpel, N. Altschuck, L. Kerkemeyer, I. Wellach, D. Becker, M. Geraedts, D. Pedrosa (Marburg, Germany)

    Objective: To implement and evaluate a novel care model for people with Parkinson’s Disease (PD), based on the following principles: proactive, person-centered, and digital (cf.…
  • 2023 International Congress

    Distinct striatal connectivity patterns in patients with Parkinson’s disease with and without urinary symptoms

    N. Piramide, R. de Micco, F. Di Nardo, M. Siciliano, G. Caiazzo, G. Tedeschi, F. Esposito, A. Tessitore (Napoli, Italy)

    Objective: To investigate the potential effect of urinary symptoms on the regional striatal functional connectivity (FC) in a cohort of drug-naïve PD patients applying a…
  • 2023 International Congress

    Genetic profile of early-onset Parkinson’s Disease patients at a movement disorders center in Brazil

    M. Costa, A. Pessoa-Neto, F. Sarmento, G. Lima, C. Silva, L. Barcelos, P. Aguiar, S. Azevedo, V. Borges, H. Ferraz (São Paulo, Brazil)

    Objective: This study aimed to identify the genetic landscape of early-onset Parkinson’s Disease (EOPD) in a cohort from a referral center in Brazil. Background: Parkinson’s…
  • 2023 International Congress

    The effect of levodopa on the blood activity of calpains in patients with Parkinson’s disease

    Z. Muruzheva, M. Absalyamova, M. Karpenko (Saint-Petersburg, Russian Federation)

    Objective: To evaluate the effect of levodopa on the blood activity of calpains in patients with PD Background: Parkinson's disease (PD) is a chronic progressive…
  • 2023 International Congress

    Dyspnea and quality of life in Parkinson’s: a mixed methods study

    M. Darabseh, A. Aburub (Amman, Jordan)

    Objective: This study aimed to explore dyspnea experiences in people living with Parkinson’s PlwP who are walking independently. Background: Dyspnea is one of the non-motor…
  • « Previous Page
  • 1
  • …
  • 97
  • 98
  • 99
  • 100
  • 101
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley